Publications by authors named "F A Ramires"
Transthyretin amyloidosis (ATTR amyloidosis) is characterized by the buildup of amyloid protein in organs like the gut and the heart. As a result, hypoperfusion, edema, and dysautonomia cause an imbalance in the gut microbiome. We aimed to identify the gut microbiome composition in ATTR amyloidosis patients with and without heart involvement, as well in controls.
View Article and Find Full Text PDFBackground: Patients with heart failure with reduced ejection fraction (HFrEF) who achieve reverse remodelling (RR) can experience a new decrease in ejection fraction (EF), and the predictors of sustained RR (SRR) are not completely understood.
Objectives: The study aims to identify predictors of SRR in patients with HFrEF after an increase in EF and evaluate SRR prognosis.
Methods: In this retrospective, observational study, we evaluated a real-life cohort of patients with HFrEF and ≥2 consecutive echocardiograms, divided according to left ventricular EF (LVEF) trajectory: no RR (NRR: 3/3 LVEF measurements < 40%), non-SRR (NSRR: second LVEF ≥ 40%, third LVEF < 40%), and SRR (SRR: second and third LVEF ≥ 40%).
Cardiovascular Computed Tomography and Magnetic Resonance Imaging Guideline of the Brazilian Society of Cardiology and the Brazilian College of Radiology - 2024.
Arq Bras Cardiol
October 2024
Assessment of right ventricular myocardial stiffness by cardiac elastography in patients with transthyretin amyloidosis.
Curr Probl Cardiol
January 2025
Article Synopsis
- Amyloidosis is a disease where misfolded proteins accumulate in tissues, often causing cardiac issues like stiffness and heart failure, particularly in transthyretin amyloidosis.
- A study involving 60 patients, including those with cardiac ATTR amyloidosis, measured right ventricular (RV) stiffness using shear wave elastography (SWE) and assessed correlations with various health metrics.
- The findings suggest that SWE is an effective, noninvasive method for evaluating RV stiffness, with an SWE threshold of ≥ 4.6 kPa indicating potential cardiac involvement, thus aiding in diagnosis and treatment.
Chronic Chagas cardiomyopathy (CCC) has unique pathogenic and clinical features with worse prognosis than other causes of heart failure (HF), despite the fact that patients with CCC are often younger and have fewer comorbidities. Patients with CCC were not adequately represented in any of the landmark HF studies that support current treatment guidelines. PARACHUTE-HF (Prevention And Reduction of Adverse outcomes in Chagasic Heart failUre Trial Evaluation) is an active-controlled, randomized, phase IV trial designed to evaluate the effect of sacubitril/valsartan 200 mg twice daily vs enalapril 10 mg twice daily added to standard of care treatment for HF.
View Article and Find Full Text PDF